Crescent Biopharma (FRA:C68) Total Assets: €172.25 Mil (As of Mar. 2026)


FRA:C68 Crescent Biopharma Inc FRA:C68
10 GF Score
Price €14.60
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma Total Assets?

Crescent Biopharma FRA:C68 10 Total Assets is €172.25 Mil as of Mar. 2026. GuruFocus rates FRA:C68 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Crescent Biopharma's Total Assets for the quarter that ended in Mar. 2026 was €172.25 Mil.

During the past 12 months, Crescent Biopharma's average Total Assets Growth Rate was 3084.60% per year.

Total Assets is connected with ROA %. Crescent Biopharma's annualized ROA % for the quarter that ended in Mar. 2026 was -42.69%. Total Assets is also linked to Revenue through Asset Turnover. Crescent Biopharma's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Crescent Biopharma  (FRA:C68) Total Assets Explanation

Total Assets is connected with ROA %.

Crescent Biopharma's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-80.56/( (205.21+172.247)/ 2 )
=-80.56/188.7285
=-42.69 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Crescent Biopharma's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0.899/( (205.21+172.247)/ 2 )
=0.899/188.7285
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Crescent Biopharma Total Assets Related Terms

Crescent Biopharma Total Assets Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Total Assets Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
Total Assets
34.01 205.21

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial 0.00 136.49 117.81 205.21 172.25
FRA:C68
10GF Score
Crescent Biopharma Inc FRA:C68
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Crescent Biopharma's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=173.372+31.838
=205.21

Crescent Biopharma's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=159.028+13.22
=172.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of €172.25 Mil mean?
Crescent Biopharma (FRA:C68) has a Total Assets of €172.25 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Crescent Biopharma and its competitors.
Is Crescent Biopharma's Total Assets too high?
Crescent Biopharma's current Total Assets is €172.25 Mil. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Total Assets compare to KYTX and ZURA?
Crescent Biopharma's Total Assets of €172.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Crescent Biopharma and its competitors. Crescent Biopharma's current Total Assets is €172.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (FRA:C68) has a current Total Assets of €172.25 Mil. The current Total Assets is €172.25 Mil. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Crescent Biopharma (FRA:C68), the current Total Assets is €172.25 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges CBIO:USA
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score

Get the complete analysis for FRA:C68

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.60
Price